ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2024 ACR Guideline for the Screening, Treatment & Management of Lupus Nephritis

From the College  |  December 2, 2025

Review 28 recommendations covering proteinuria screening, biopsy indications & triple therapy regimens for lupus nephritis.

Ableism—Not to Be Overlooked in Rheumatology Practices: Rheum for Everyone, Episode 26 (video)

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  December 1, 2025

In this episode, Dr. Kumar talks about the insidious nature of ageism and how rheumatologists can combat it.

Rheuminations: Can We Now Control the Wolf?

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  December 1, 2025

Lupus has always had a reputation for being a wild, unrestrained and enigmatic entity. In fact, the very name lupus comes from the Latin word for wolf, a gift from our Roman predecessors who saw a resemblance between lupus rashes and a wolf’s bite. Given the limitations of immunology back then, it is an incredibly…

Obinutuzumab Aids Standard Therapy for Lupus Nephritis

Deborah Levenson  |  December 1, 2025

Phase 3 REGENCY data: Obinutuzumab & standard therapy improve complete renal response rates in active lupus nephritis patients.

FDA Approvals: Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  November 30, 2025

Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…

Trials Find Potential Treatments for SLE, Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  November 29, 2025

In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…

Belimumab Promising for Children with Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  November 28, 2025

In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…

Kidney Biopsy in Lupus Nephritis

Ruth Jessen Hickman, MD  |  November 27, 2025

As part of a session on lupus nephritis at ACR Convergence 2023, Simone Appenzeller, MD, PhD, shared perspectives on the importance of biopsy to inform the diagnosis, prognosis and treatment of the condition, with an emphasis on childhood disease. Prompt diagnosis and treatment of lupus nephritis is perhaps even more important for children than for…

The ACR Releases New Lupus Nephritis Guideline

Ruth Jessen Hickman, MD  |  November 26, 2025

At a session of ACR Convergence 2024, speakers shared key elements of the new guideline on the screening, treatment and overall management of lupus nephritis in children and adults.1 This guideline attempts to balance the risks of medication side effects with the important goal of preserving kidney function. This is the ACR’s first lupus guideline…

Neutrophilic Inflammation in Spondyloarthritis

Michael Cammarata, MD  |  November 25, 2025

CHICAGO—In the basic science session, Beyond NETs: Alternative Roles of Neutrophils in Spondyloarthritis, neutrophils are explored as a common pathophysiologic thread among the spondyloarthropathies. In this two-part talk, Dennis McGonagle, PhD, professor of investigative rheumatology at the Leeds Institute of Rheumatic and Musculoskeletal Medicine at St James Hospital, Leeds, England, opens by examining the role…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 842
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences